Ikonisys pronounces the beginning of a distribution collaboration with BioVendor Laboratory Drugs for the distribution of the Ikoniscope20 system within the Jap European market

PARIS, September 13, 2022–(BUSINESS WIRE)–Regulatory information:

Ikonisys SA (ISIN code: FR00140048X2 / Mnemonic: ALIKO) (Paris:ALIKO), an organization specializing within the early and exact detection of most cancers with a singular totally automated resolution for medical diagnostic laboratories, pronounces the beginning of its first distribution collaboration for the sale of the Ikoniscope20 digital fluorescence microscope resolution within the Jap European market.

As introduced throughout Ikonisys’ IPO, Ikonisys’ go-to-market technique will revolve round a direct/non-direct gross sales mannequin, going direct with its personal gross sales drive in the USA and main European nations, and by working with certified distributors with a robust market presence within the subject of molecular pathology of their respective markets. The partnership with BioVendor will initially concentrate on their residence markets, the Czech and Slovak Republics, with the potential of extending the collaboration to Austria and the UK later.

Following execution of the distribution collaboration settlement, BioVendor will current the Ikoniscope20 system on the fifty fifth Annual Cytogenetics and Genetics Convention in Prague, Czech Republic on September 15-16, 2022.

Jurgen Schipper, Business Director of Ikonisysstated: “We’re more than happy to have entered right into a partnership with BioVendor, a extremely respected diagnostics distributor and producer with a robust market presence in Jap Europe and different European markets. confirms the feasibility of our enterprise mannequin and demonstrates our We’re assured that the collaboration with BioVendor may have a major affect on the usage of the Ikoniscope20 system in molecular pathology laboratories within the Jap European market.

Eva Svobodova, Business Director of BioVendorstated:
“We recognize the belief and alternative supplied by Ikonisys. We’re keen about setting new requirements within the IVD market. With Ikonisys, we’re in a position to supply an incredible, modern resolution for molecular pathologists. We sit up for extending our present resolution based mostly on the skilled data of Ikonisys and BioVendor LM.”

About Ikonisys

Ikonisys SA is a cell diagnostics firm based mostly in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specializing within the early and correct detection of most cancers. The corporate develops, produces and markets the proprietary Ikoniscope20® platform, a completely automated resolution designed to offer correct and dependable detection and evaluation of uncommon and really uncommon cells. Ikonisys has acquired FDA clearance for a number of automated diagnostic functions, that are additionally marketed in Europe beneath CE certification. With its breakthrough fluorescence microscopy platform, the corporate continues to develop a stream of latest assessments, together with liquid biopsy assessments based mostly on circulating tumor cells (CTCs).

For extra info, go to www.Ikonisys.com

About BioVendor LM

At BioVendor LM, we provide a beautiful portfolio of established and modern merchandise and applied sciences for medical biochemistry, immunology, hematology, microbiology, molecular biology and POCT. We pay particular consideration to glorious technical assist {and professional} recommendation – from the number of a selected product to a whole design for laboratory automation. We imagine that trendy diagnostics contribute to more practical remedy of sufferers. Inside the BioVendor Group, we cooperate within the growth of modern merchandise and introduce them into laboratory observe.

Along with the top workplace within the Czech Republic, we’re additionally represented in Slovakia. BioVendor Slovakia sro presents its clients a full vary of services – from the distribution of diagnostic kits to turnkey laboratory tools. BioVendor LM and Ikonisys will take part within the Nationwide Congress of the Society of Medical Genetics and Genomics ČLS JEP on September 15-16 on the Wellness Lodge STEP in Prague.

Disclaimer

This press launch incorporates forward-looking statements in regards to the prospects and growth of the Firm. These statements are typically recognized by means of the long run, conditional and forward-looking phrases reminiscent of “imagine”, “goal”, “anticipate”, “intend”, “estimate”, “imagine”. “, “ought to”, “may”, “will” or “will” or, the place relevant, the adverse type of these phrases or every other variation or related expression. This info isn’t historic knowledge and shouldn’t be interpreted as a assure that the information and knowledge acknowledged will happen. This info is predicated on knowledge, assumptions and estimates thought of cheap by the Firm. It’s topic to vary or change as a consequence of uncertainties associated to the surroundings financial, monetary, aggressive and regulatory This info incorporates knowledge referring to the intentions, estimates and aims of the Firm regarding particularly the market, technique, development, outcomes, monetary state of affairs and Firm money. The forward-looking info contained on this press launch speaks solely as of the date of this press launch. The Firm doesn’t undertake to replace the forward-looking info contained on this press launch, besides as required by relevant legislation or regulation. The Firm operates in a aggressive and quickly altering surroundings and subsequently can not anticipate all of the dangers, uncertainties or different elements that might have an effect on its enterprise, their potential affect on its enterprise or the extent to which the materialization of a threat or a mix of dangers may trigger outcomes to vary materially from these expressed in any forward-looking info, it being remembered that none of this forward-looking info constitutes a assure of precise outcomes.

See the supply model on businesswire.com: https://www.businesswire.com/news/home/20220913006063/en/

contacts

Ikonisys
Alessandro Mauri
CFO
investors@ikonisys.com

NewCap
Louis Victor Delouvrier
Investor Relations
Ikonisys@newcap.eu
Such. : +33 (0)1 44 71 94 92

NewCap
Nicolas Merigeau
Media Relations
Ikonisys@newcap.eu
Such. : +33 (0)1 44 71 94 98

Leave a Comment